Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06194123 · ClinicalTrials.gov registry record · NA
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
A NA study of Xerostomia and Halitosis, sponsored by Tufts University.
- Active
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06194123: Active NA study of Xerostomia and Halitosis, sponsored by Tufts University.
NCT06194123 is a NA study of Xerostomia and Halitosis that is active but no longer recruiting, run by Tufts University. The registered enrollment target is 27 participants, below the 93-participant average among 13 other Xerostomia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06194123, a NA study of Xerostomia and Halitosis, is active but no longer recruiting, sponsored by Tufts University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.
Primary Outcome
To observe presence and degree of reduction in the self-reported subjective perception of dryness in the oral cavity at different time intervals after the application of a Whitening Agent with Emulsion Gel in Xerostomic Population
Conditions Studied
Interventions
- OTHER Crest Daily Whitening Serum
Study Locations (1)
Massachusetts
- Tufts University School of Dental Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-02-01 |
| Phase | NA |
What the registry record for NCT06194123 still lists
NCT06194123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 93-participant average among 13 other Xerostomia trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Xerostomia appearing as the primary indexed condition, and to 1 intervention - of which Crest Daily Whitening Serum is the first listed.
NCT06194123 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06194123 about?
NCT06194123 is a clinical study titled "Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis". The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.
What is the current status of trial NCT06194123?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2024-02-01. Estimated completion is 2027-02-01.
What conditions does trial NCT06194123 study?
This clinical trial studies the following conditions: Xerostomia, Halitosis.
What interventions are being tested in trial NCT06194123?
The interventions under investigation include: Crest Daily Whitening Serum (OTHER).
Who is sponsoring clinical trial NCT06194123?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06194123 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Xerostomia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06194123's enrollment target sits among peer trials
27 11th of 13 higher than 3 of 13 other Xerostomia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Xerostomia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SaliPen Human Factors Study for OTC Labeling
COMPLETED · NA
-
Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects
COMPLETED · NA
-
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
COMPLETED · NA
-
Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray
COMPLETED · NA
-
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI